Equities

Medistim ASA

Medistim ASA

Actions
Health CareMedical Equipment and Services
  • Price (NOK)140.50
  • Today's Change2.50 / 1.81%
  • Shares traded20.33k
  • 1 Year change-26.82%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in NOK

The one analyst offering a 12 month price target expects Medistim ASA share price to rise to 172.00 in the next year from the last price of 140.50.
High22.4%172.00
Med22.4%172.00
Low22.4%172.00

Dividends in NOK

In 2023, Medistim ASA reported a dividend of 4.50 NOK, equaling last years dividend. The analyst covering the company expects dividends of 4.50 NOK for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in NOK

On Oct 24, 2024, Medistim ASA reported 3rd quarter 2024 earnings of 1.28 per share.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+2.71%
Medistim ASA reported annual 2023 earnings of 5.67 per share on Feb 28, 2024.
Average growth rate+11.42%
More ▼

Revenue history & estimates in NOK

Medistim ASA had 3rd quarter 2024 revenues of 132.76m. This missed the 136.00m estimate of the one analyst following the company. This was 2.70% above the prior year's 3rd quarter results.
Average growth rate+1.96%
Medistim ASA had revenues for the full year 2023 of 526.36m. This was 7.00% above the prior year's results.
Average growth rate+9.91%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.